Home page > Press release

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
 
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for...
1/5
ARCHIVE PRESS RELEASE
Европа одобряет Холоклар (HOLOCLAR®) - первый медицинский продукт на основе стволовых клеток
Кьези Фармацевтичи (Chiesi Farmaceutici) и Корнерстоун Серапьютикс (Cornerstone Therapeutics) объявляют о подписании соглашения о слиянии